Abbott Laboratories (ABT)
Abbott (ABT) Rises As Market Takes a Dip: Key Facts
Abbott (ABT) closed the most recent trading day at $103.09, moving +1.12% from the previous trading session.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain?
FDA approval for TactiFlex Duo expands ABT's AFib ablation portfolio with dual PFA and RF energy options, supporting broader U.S. adoption.
Here's Why Abbott (ABT) Fell More Than Broader Market
Abbott (ABT) concluded the recent trading session at $105.52, signifying a -2.59% move from its prior day's close.
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Abbott (ABT) settling at $110.47, representing a +1.41% change from its previous close.
Two Recessions Couldn't Stop These 4 Healthcare Stocks From Raising Dividends
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns.
Why Abbott (ABT) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
Abbott (ABT) concluded the recent trading session at $111.59, signifying a -2.2% move from its prior day's close.
The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?
Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.
Here's What Is Shaping Abbott's Diagnostics Growth
ABT's Diagnostics growth is being reshaped as weaker respiratory testing offsets healthy routine demand and 13% cancer diagnostics growth.
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst
ABT's Medical Devices growth is fueled by electrophysiology, expanding CGM adoption and a cardiovascular pipeline extending into 2029 and beyond.
Abbott Laboratories: Reasonably Valued After Surge, But Still An Attractive Buy Long-Term
Abbott Laboratories remains a buy, with accelerating earnings growth, margin expansion, and robust segment performance following Q2's double beat and guidance raise. ABT's Exact Sciences acquisition strengthens its long-term growth runway, supporting a raised EPS outlook and 10.4% CAGR over the next six years. Despite recent price appreciation, ABT trades below its 5-year forward P/E average, offering a 2.5% yield and a potential 37% upside to a $151 price target.
